Affibody Announces Presentation of Interim Data from Phase I/II Clinical Trial of ABY-035 at European Academy of Dermatology and Venereology
September 6, 2017
Solna, Sweden, September 6, 2017. Affibody AB (“Affibody”), a clinical stage next generation biopharmaceutical company developing a portfolio of innovative drug projects, today announced that interim data from the ongoing Phase I/II study of ABY-035 will be presented at the 26th European Academy of Dermatology and Venereology (EADV) Congress to be held in Geneva September 13-17, 2017.
Title: Blocking IL-17A with femtomolar affinity using the novel engineered Affibody ligand trap ABY-035: Interim results from a phase I, first in human study.
Presenter: Prof. Fredrik Frejd, CSO Affibody AB
Session: D3T01.1 Late Breaking News
Date and Time: Saturday September 16, 2017, 8:45 AM – 9:00 AM
Location: PALEXPO, Room 1.
Affibody is a clinical stage Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.
The company is currently developing four proprietary programs. The first three are therapeutic programs that targets psoriasis, autoimmune diseases, and liver diseases respectively. The fourth program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.
Affibody also has ongoing commercial relationships with several companies such as AbClon, Biotest, Daewoong, Daiichi Sankyo, GE Healthcare, Nordic Nanovector, and Swedish Orphan Biovitrum.
Further information can be found at: www.affibody.com